Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management

Ali Al-Janabi; Zenas Z N Yiu

doi:10.2147/PTT.S328575

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management

Ali Al-Janabi, Zenas Z N Yiu

Division of Musculoskeletal & Dermatological Sciences (L5)

Research output: Contribution to journal › Article › peer-review

103 Downloads (Pure)

Abstract

Biologics targeting Th1/Th17 cytokines have revolutionised psoriasis treatment. In addition to treatment effectiveness, it is important to define and understand the long-term risks of biologic therapy in order to guide therapy selection and minimise these risks for patients where possible. This review article summarises available evidence from trial data, observational studies and pharmacovigilance registries to explore key long-term risks of biologic treatment, and how these risks might be managed in clinical practice.

Original language	English
Pages (from-to)	1-14
Number of pages	14
Journal	Psoriasis: Targets and Therapy
Volume	12
DOIs	https://doi.org/10.2147/PTT.S328575
Publication status	Published - 6 Jan 2022

Access to Document

10.2147/PTT.S328575Licence: CC BY-NC

PTT-328575-biologics-in-psoriasis--updated-perspectives-on-long-term-saFinal published version, 476 KBLicence: CC BY-NC

Cite this

@article{4ef6deb1694a4b869128c84f194fdfe9,

title = "Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management",

abstract = "Biologics targeting Th1/Th17 cytokines have revolutionised psoriasis treatment. In addition to treatment effectiveness, it is important to define and understand the long-term risks of biologic therapy in order to guide therapy selection and minimise these risks for patients where possible. This review article summarises available evidence from trial data, observational studies and pharmacovigilance registries to explore key long-term risks of biologic treatment, and how these risks might be managed in clinical practice.",

author = "Ali Al-Janabi and Yiu, \{Zenas Z N\}",

note = "{\textcopyright} 2022 Al-Janabi and Yiu.",

year = "2022",

month = jan,

day = "6",

doi = "10.2147/PTT.S328575",

language = "English",

volume = "12",

pages = "1--14",

journal = "Psoriasis: Targets and Therapy ",

issn = "2230-326X",

publisher = "Dove Medical Press ",

}

TY - JOUR

T1 - Biologics in Psoriasis

T2 - Updated Perspectives on Long-Term Safety and Risk Management

AU - Al-Janabi, Ali

AU - Yiu, Zenas Z N

PY - 2022/1/6

Y1 - 2022/1/6

N2 - Biologics targeting Th1/Th17 cytokines have revolutionised psoriasis treatment. In addition to treatment effectiveness, it is important to define and understand the long-term risks of biologic therapy in order to guide therapy selection and minimise these risks for patients where possible. This review article summarises available evidence from trial data, observational studies and pharmacovigilance registries to explore key long-term risks of biologic treatment, and how these risks might be managed in clinical practice.

AB - Biologics targeting Th1/Th17 cytokines have revolutionised psoriasis treatment. In addition to treatment effectiveness, it is important to define and understand the long-term risks of biologic therapy in order to guide therapy selection and minimise these risks for patients where possible. This review article summarises available evidence from trial data, observational studies and pharmacovigilance registries to explore key long-term risks of biologic treatment, and how these risks might be managed in clinical practice.

U2 - 10.2147/PTT.S328575

DO - 10.2147/PTT.S328575

M3 - Article

C2 - 35024352

SN - 2230-326X

VL - 12

SP - 1

EP - 14

JO - Psoriasis: Targets and Therapy

JF - Psoriasis: Targets and Therapy

ER -

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management

Abstract

Access to Document

Fingerprint

Cite this